Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoMethylome Sciences has entered into a collaboration with GlaxoSmithKline Biologicals to develop DNA methylation biomarkers for use in the personalization of cancer treatment with certain immunotherapeutics in development by GSK Biologicals.
Subscribe to our email newsletter
The collaboration is supported by a Wallonia (BioWin) research grant that was announced in April 2007. Financial details of the agreement have not been disclosed.
Jim DiGuiseppi, chief technology officer of OncoMethylome, said: “We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals. We are pleased that GSK Biologicals has chosen OncoMethylome for this collaboration.”